TickerHumSide-by-side comparison
Johnson & Johnson vs Merck & Co.
As of Nov 11, 2026, P/E is 42.3x for Johnson & Johnson vs 147.9x for Merck & Co.; P/S is 6.7x for Johnson & Johnson vs 5.4x for Merck & Co.; revenue growth is 7.8% for Johnson & Johnson vs 4.9% for Merck & Co.; net margin is 16.2% for Johnson & Johnson vs 3.6% for Merck & Co..
What stands out
- Johnson & Johnson is cheaper on earnings: 42.3x P/E vs 147.9x for Merck & Co..
- Johnson & Johnson carries less debt relative to equity: 0.44 vs 1.11 for Merck & Co..
- Merck & Co.'s shares did better over the past year: +60.1% vs +43.2% for Johnson & Johnson.
- Johnson & Johnson scores higher on TickerHum's ratings: 60/100 vs 50/100 for Merck & Co..
Key metrics
| Metric | JNJ | MRK |
|---|---|---|
| Price | $278.45 | $146.45 |
| Market cap | $670.32B | $361.04B |
| P/E | 42.3x (#1) | 147.9x (#2) |
| P/S | 6.7x (#2) | 5.4x (#1) |
| Revenue growth | 7.8% (#1) | 4.9% (#2) |
| Operating margin | — | — |
| Net margin | 16.2% (#1) | 3.6% (#2) |
| Debt / equity | 0.44 (#1) | 1.11 (#2) |
| 1-year return | +43.2% (#2) | +60.1% (#1) |
| Research score | 60/100 (#1) | 50/100 (#2) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Johnson & Johnson (JNJ) — Drug Manufacturers—General
- Merck & Co., Inc. (MRK) — Drug Manufacturers—General